These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 23379777)
1. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs. Lin CJ; Zimmerman RK; Smith KJ Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777 [TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090 [TBL] [Abstract][Full Text] [Related]
4. Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults. Wateska AR; Nowalk MP; Altawalbeh SM; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ J Am Geriatr Soc; 2024 Aug; 72(8):2423-2433. PubMed ID: 38822745 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Smith KJ; Lee BY; Nowalk MP; Raymund M; Zimmerman RK Vaccine; 2010 Nov; 28(48):7620-5. PubMed ID: 20887828 [TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan. Hoshi SL; Kondo M; Okubo I PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. You JH; Wong WC; Ip M; Lee NL; Ho SC J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic. Smith KJ; Raymund M; Nowalk MP; Roberts MS; Zimmerman RK Am J Manag Care; 2010 Mar; 16(3):200-6. PubMed ID: 20225915 [TBL] [Abstract][Full Text] [Related]
9. Characteristics of long-term care facilities associated with standing order programs to deliver influenza and pneumococcal vaccinations to residents in 13 states. Shefer A; McKibben L; Bardenheier B; Bratzler D; Roberts H J Am Med Dir Assoc; 2005; 6(2):97-104. PubMed ID: 15871883 [TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia. Lara C; De Graeve D; Franco F Value Health Reg Issues; 2018 Dec; 17():21-31. PubMed ID: 29626706 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis. Wateska AR; Nowalk MP; Zimmerman RK; Smith KJ; Lin CJ BMC Infect Dis; 2018 Jan; 18(1):52. PubMed ID: 29370768 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis. Michaelidis CI; Zimmerman RK; Nowalk MP; Smith KJ Value Health; 2013; 16(2):311-7. PubMed ID: 23538183 [TBL] [Abstract][Full Text] [Related]
13. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis. Brydak L; Roiz J; Faivre P; Reygrobellet C Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294 [TBL] [Abstract][Full Text] [Related]
14. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis. Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Sisk JE; Whang W; Butler JC; Sneller VP; Whitney CG Ann Intern Med; 2003 Jun; 138(12):960-8. PubMed ID: 12809452 [TBL] [Abstract][Full Text] [Related]
17. Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations. Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ Am J Prev Med; 2020 Apr; 58(4):487-495. PubMed ID: 32001052 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China. Chen D; Ye Z; Pi Z; Mizukami S; Aoyagi K; Jiang Y Vaccine; 2021 Apr; 39(16):2237-2245. PubMed ID: 33757667 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of a toolkit to introduce standing orders for influenza and pneumococcal vaccination in adults: a multimodal pilot project. Nowalk MP; Nutini J; Raymund M; Ahmed F; Albert SM; Zimmerman RK Vaccine; 2012 Sep; 30(41):5978-82. PubMed ID: 22835736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]